CB-183,315 + Placebo + Vancomycin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection
Conditions
Clostridium Difficile Infection, Diarrhea
Trial Timeline
Apr 1, 2010 → May 13, 2011
NCT ID
NCT01085591About CB-183,315 + Placebo + Vancomycin
CB-183,315 + Placebo + Vancomycin is a phase 2 stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01085591. Target conditions include Clostridium Difficile Infection, Diarrhea.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01085591 | Phase 2 | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection